



ALK  
Investor Relations Department  
BÃge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)

Sign-up for Email alerts [↗](#)

#### OMX: ALKB

Last Trade:	898.00
Trade Time:	4:59 PM ET Nov 20, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	839.00 - 1133.00
Volume	1,341,600

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*Nov 10, 2017*

[Nine-month interim report \(Q3\) 2017](#)

*Nov 3, 2017*

[ALK appoints Søren Jelert as new Chief Financial Officer](#)

*Nov 3, 2017*

[Release date of nine-month interim report \(Q3\) 2017 and audio cast](#)

*Oct 12, 2017*

[Notification of ownership in ALK](#)

*Sep 27, 2017*

[ALK's partner, Torii, gains approval for Japanese cedar SLIT-tablet in Japan](#)

## Upcoming Events [\[ View all \]](#)

*Nov 23, 2017*

[IR roadshow, Oslo](#)

*Dec 5, 2017*

[Carnegie Healthcare Day, New York](#)